SCHEMBL6649889

SCHEMBL6649889

O=C(O)[C@H](CS(=O)(=O)Cc1ccccc1)OC(=O)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
FKBP1A P62942 1/20 0.44
TP53 P04637 1/20 0.44
ALDH1A1 P00352 5/20 0.43
CTSS P25774 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
CYP2C19 P33261 1/20 0.42
MMP8 P22894 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6649897 1.00 KMT2A (0.51) KMT2AMEN1NPSR1FKBP1ATP53
SCHEMBL7287129 0.82 KMT2A (0.58) KMT2AMEN1NPSR1FKBP1ATP53
SCHEMBL7287136 0.82 KMT2A (0.58) KMT2AMEN1NPSR1FKBP1ATP53
SCHEMBL6628710 0.81 CTSS (0.47) KMT2AMEN1NPSR1CTSS
SCHEMBL6628713 0.81 CTSS (0.47) KMT2AMEN1NPSR1CTSS
SCHEMBL6063336 0.80 CTSS (0.44) KMT2AMEN1NPSR1CTSS
SCHEMBL6063338 0.80 CTSS (0.44) KMT2AMEN1NPSR1CTSS
SCHEMBL9355043 0.78 KMT2A (0.53) KMT2AMEN1NPSR1FKBP1ATP53
SCHEMBL9355033 0.78 KMT2A (0.53) KMT2AMEN1NPSR1FKBP1ATP53
SCHEMBL2163129 0.78 MMP8 (0.50) KMT2AMEN1NPSR1FKBP1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE KMT2A 4623/4885MEN1 4485/4885NPSR1 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.